Profit Margin: Net Income as a portion of total sales revenue. Calculated as: Net Income / Total Revenues
CytomX Therapeutics, Inc. (CTMX) had Profit Margin of -1184.72% for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
$1.69M |
|
$-20.00M |
|
-- |
|
$1.69M |
|
$25.19M |
|
$-23.50M |
|
$3.56M |
|
$-19.94M |
|
$-19.94M |
|
$-20.00M |
|
$-20.00M |
|
$-20.00M |
|
$-20.00M |
|
$-23.50M |
|
$-24.45M |
|
219.11M |
|
219.11M |
|
$-0.09 |
|
$-0.09 |
|
| Balance Sheet Financials | |
$356.05M |
|
$2.52M |
|
$8.63M |
|
$364.68M |
|
$45.53M |
|
-- |
|
$34.26M |
|
$79.79M |
|
$284.89M |
|
$283.61M |
|
$284.89M |
|
218.00M |
|
| Cash Flow Statement Financials | |
$-26.97M |
|
$-186.83M |
|
$235.09M |
|
$14.19M |
|
$35.49M |
|
$21.30M |
|
$10.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.82 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1392.30% |
|
-1392.30% |
|
-- |
|
-1181.10% |
|
|
Profit Margin |
-1184.72% |
$-27.26M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
3.37 |
|
26.71 |
|
-7.02% |
|
-7.05% |
|
-5.48% |
|
-7.02% |
|
$1.31 |
|
$-0.12 |
|
$-0.12 |
|